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ABSTRACT  The Madin-Darby  canine  kidney  (MDCK) cell  line,  derived  from  distal tubule/ 
collecting duct, expresses differentiated  properties of renal tubule epithelium  in culture. We 
studied the expression of adrenergic receptors in MDCK to examine the role of catecholamines 
in the regulation of renal function.  Radioligand-binding studies demonstrated, on the basis of 
receptor affinities of subtype-selective adrenergic agonists and antagonists, that MDCK cells 
have both at- and ~2-adrenergic receptors. To determine whether these receptor types were 
expressed by the same cell, we developed  a number of clonal MDCK cell lines. The clonal 
lines had stable but unique morphologies reflecting heterogeneity in the parent cell line. Some 
clones expressed only/~2-adrenergic receptors and were nonmotile, whereas others expressed 
both  ~t-  and /~2-receptors and demonstrated  motility on the culture  substrate at low  cell 
densities. In one clone, a- and/~-receptor  expression was stable for more than 50 passages. 
Catecholamine  agonists increased phosphatidylinositol  turnover by activating  a-adrenergic 
receptors and cellular cyclic  adenosine monophosphate  accumulation  by activating/3-adre- 
nergic receptors. Guanine nucleotide decreased the affinity of isoproterenol for the ~2-receptor 
but did not alter the affinity  of epinephrine  for the c~l-receptor. These results show that c~l- 
and/32-receptors can be expressed by a single renal tubular  cell and that the two receptors 
behave as distinct entities in terms of cellular response and receptor regulation. Heterogeneity 
of adrenergic receptor expression in MDCK clones may reflect properties of different  types 
of renal tubule cells. 
Catecholamines regulate a variety of cellular functions in the 
mammalian kidney, including tubule water and ion reabsorp- 
tion, renin release, renal hemodynamics, and gluconeogenesis 
(20,  35).  The influence of renal sympathetic nerves (which 
release catecholamines as neurotransmitters) on renal func- 
tion has been discussed in several reviews (1,  6,  32).  Cate- 
cholamines act  on  target  cells  by  initially binding  to  cell 
surface receptors, and we and others (20, 41-43) have identi- 
fied a~-, ~2-, B~-, and/~2-adrenergic receptors in membrane 
preparations of  the kidney cortex by radioligand-binding tech- 
niques. However, the sites of  action of  adrenergic agents along 
the nephron have not been clearly defined. Determination of 
the  location of catecholamine action within  the  kidney is 
particularly important to distinguish indirect adrenergic ef- 
fects (resulting from changes in  vascular tone) from direct 
effects on epithelial transport and metabolism. The kidney 
consists of segments that are anatomically and functionally 
distinguishable, yet each segment may contain several mor- 
phologically distinct cell types (8). To understand the regula- 
tion of renal function by catecholamines and  sympathetic 
nerves, it therefore is important to study homogeneous pop- 
ulations of renal cells. Such populations may be found in the 
established  renal  cell  lines,  which  have  provided valuable 
information regarding kidney transport and metabolism (15). 
We chose the Madin-Darby canine kidney (MDCK) ~ cell 
line as a model system in which to examine the actions of 
catecholamines on renal tubule epithelium. The MDCK cell 
line was established in  1958  from normal dog kidney (12). 
MDCK cells retain differentiated properties of renal tubule 
~Abbreviations  used  in  this  paper.  MDCK, Madin-Darby canine 
kidney cells; and PtdIns, phosphatidylinositol;  ICYP, iodocyanopin- 
dolol; IHEAT, iodo-2-[/3(4-hydroxyphenyl)ethylaminomethyl]tetra- 
lone. 
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port (28). These cells appear to be derived from distal tubule/ 
collecting duct because of their enzyme markers (38),  mor- 
phologic features (47), and antigenic determinants (16). Cells 
of the distal  nephron are likely target sites for the catechol- 
amines. The basolateral surface of the distal tubule is directly 
innervated by renal sympathetic fibers, and the distal nephron 
is the  most responsive segment to B-adrenergic  agonists  as 
measured by cAMP accumulation (7). The presence of both 
a- and ~-adrenergic  responses in MDCK  cells has been re- 
ported.  In these cells, a-adrenergic  agonists stimulate arachi- 
donic acid metabolism (23) and K + effiux (3).  ~-Adrenergic 
agonists  increase cyclic adenosine  monophosphate  (cAMP) 
levels (38,  39) and transepithelial  CI- secretion (2).  The ad- 
renergic receptor subtype specificities of these responses have 
not been identified, although knowledge of the nature of these 
subtypes  is  important  for  understanding  the  mechanisms 
mediating target cell responses (11) and for identifying endog- 
enous agonists and exogenous agonists and antagonists  that 
will preferentially  occupy the target cell receptors  (1, 6, 20, 
32, 35). Moreover, several investigators  (22, 24, 37, 47) have 
presented  evidence that MDCK  is not a homogeneous cell 
line. We, therefore, addressed the following questions: (a) Are 
a- and ~-adrenergic receptors present on renal tubule epithe- 
lium? (b) If so, which adrenergic  subtype(s)  are present? (c) 
Are a- and ~-adrenergic  receptors  coexpressed by the same 
epithelial cell? (d) Are responses to a- and ~-adrenergic ago- 
nists independently mediated? 
In this paper, we describe the characterization  of a- and ~- 
adrenergic receptors  in MDCK cells in terms of their ligand 
specificities,  guanine nucleotide regulation,  and intracellular 
second-messenger systems.  We have developed a number of 
clonal MDCK cell lines with different morphologic features 
and  different adrenergic  receptor  expression.  We  conclude 
that: (a) MDCK cells express am- and ~2-adrenergic receptors; 
(b) MDCK is a heterogeneous cell line consisting of at least 
two stable cell types,  one with both a~- and Be-receptors and 
the other with only ~2-receptors; (c) in a clonal cell line derived 
from parent MDCK cells, al- and ~2-agonists mediate discrete 
intracellular responses that are independently regulated. Pre- 
liminary reports of some of these findings have been presented 
in abstract form (29, 30). 
MATERIALS  AND  METHODS 
Materials:  The following compounds were received  as gifts  from  the 
sources  indicated:  (-)-epinephrine,  (+)-epinephrine,  and (-)-norepinephrine 
(+)-bitartrate salts (Stealing Winthrop Research Institute, Rennselear, NY); (-)- 
propranolol HC1, (+)-propranolol  HCI (Ayerst Laboratories, New York); phen- 
tolamine mesylate, clonidine (Geigy Pharmaceutical,  Summit, NJ); cyanopin- 
dolol  HCI  (Sandoz  Inc.,  Basel,  Switzerland);  prazosin  (Pfizer  Inc.,  Groton, 
CT);  practolol  (ICI  Americas,  Inc.,  Wilmington,  DE);  2[~-(4-hydroxy- 
phenyl)ethylaminomethyl]tetralone  HCI  (Beiersdorf  AG,  Hamburg,  Federal 
Republic of Germany); and IPS 339 (Dr. Kenneth Minneman, Emory Univer- 
sity,  Atlanta, GA). The  following radiochemicals  were purchased  from  the 
sources  indicated:  carrier-free  Na~25I (New England  Nuclear,  Boston,  MA, 
Amersham Corp.,  Arlington  Hts., IL); m vo-[2H]inositol,  [3H]prazofin (Amer- 
sham); [3H]yohimbine (New England Nuclear). Formula 946 liquid scintillation 
cocktail  was from New England  Nuclear.  Cell  culture  media and sera were 
from  Grand  Island  Biological  Co.,  Grand Island,  NY.  Plasticware  for  cell 
culture was manufactured  by Falcon Labware, Div. of Becton,  Dickinson & 
Co. (Oxnard,  CA), Costar (Cambridge,  MA), or Lux Scientific  Corp. (Naper- 
ville, IL). All other reagents were from standard sources. 
Preparation  of  [12Sl]lodocyanopindolol  ([12SlJICYP)  and 
[12Sl]lodo_ 2_[l~(4_hydroxyphenyl)ethylaminomethyl]tetralone 
([12Sl]IHEA 7-):  Cyanopindoiol (CYP) was iodinated by minor modification 
of the method of Engel et al. (10). The reaction mixture contained 20 #g CYP, 
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10 #1 13.5 mM HCI, 20 #1 potassium phosphate buffer (0.3 M, pH 7.6), 2 mCi 
cartier-free Nan~I, and 20 #1 chloramine T in aqueous solution (0.34 mg/ml). 
The mixture was incubated for 5 min at room temperature, after which the 
reaction was stopped by the addition of 300 ~! of aqueous Na2S203 (6.3 mM). 
NaOH (10 #1 of I N) was then added, and the reaction mixture was extracted 
four times with 300 #1 0.01%  phenol in ethylacetate. The combined washes 
were concentrated under N2 and then subjected to ascending paper chromatog- 
raphy at room temperature on 3-ram paper (22  ×  24 cm) (Whatman Ltd., 
Clifton, NJ) with 0.01% phenol in 0.1 M ammonium formate (pH 8.5) as the 
solvent (running time ~4 h). The iodinated product migrated with an Rf of 
0.09 and was extracted from the appropriate strip of the chromatogram with 
0.01%  phenol in methanol for ~24 h at -20°C. The [~25I]ICYP migrated as 
a single spot when subjected to thin-layer chromatography on silica gel uni- 
plates (Analtech  Inc.,  Newark,  DE)  with  pyridine/glacial acetic acid/water 
(0.33:0.6:9.07,  vol/vol/vol) as the solvent. [I251]ICYP was stable for at least 12 
wk when stored as a  100 nM solution in 0.01% phenol in methanol. 
2[fl-(4-HydroxylphenyDethylaminomethyl]tetralone  (HEAT) was iodinated 
by a modification of the method of Engel and Hoyer (9), which is the same as 
that described above for [m'sI]ICYP except the reaction time was 1 min. When 
subjected to ascending paper chromatography, the product migrated with an 
Rf of 0.13. The [1251]IHEAT migrated as a single spot when subjected to thin- 
layer chromatography on  silica  gel  with  pyridine/glacial  acetic  acid/water 
(0.33:0.6:9.07,  vol/vol/voi) as the solvent (Rf =  0.7).  When methanol/chloro- 
form (30:50,  vol/vol) was used as solvent, the product ran with an Rf of 0.79, 
and trace radiochemical impurities with Rrs of 0.25 and 0.92 were  detected. 
The [~25I]IHEAT was stable for at least 4 mo when stored at -20°C as a  100 
nM solution in 0.01%  phenol in methanol; the amounts of the radiochemical 
impurities did not increase during storage. 
Cell Culture:  Low-passage  MDCK cells (catalog No. CCL34, pat~age 
53) were obtained from the American Type Culture Collection (ATCC, Rock- 
ville, MD). ATCC-derived cells of a later passage number were obtained from 
Dr. Milton Saier, Department of Biology, University of California, San Diego. 
The cells  were  maintained in Dulbecco's modified Eagle's medium supple- 
merited with 7.5%  heat-inaetivated horse serum, 2.5%  heat-inactivated fetal 
calf serum, 15 mM HEPES, and 20/~g/ml gentamycin. Serum-free medium 
was prepared according to the formulation of Taub et al. (46). Confluent cells 
were subcultured once weekly with a trypsin-EDTA solution and were inocu- 
lated at dilution ratios between 1:4 and 1:10 into 250-ml culture flasks contain- 
ing 20 ml of  medium. The cells were maintained  in a humidified 37"C incubator 
in an atmosphere of 90% air and 10% CO2. Clonal cell lines were obtained by 
limiting dilution (<0.5 cell/ml) of single-cell suspensions prepared from sub- 
confluent cultures into 24-well  plates (1  ml/well; 2  cm  2 surface area/well). 
Cional growth was confirmed by frequent microscope inspection of the wells. 
Cell  lines were  stored at  -70°C af~cr detachment with trypsin-EDTA and 
resuspension in growth medium containing 10% dimethyl sulfoxide (vol/vol). 
Membrane Preparation:  Cell  membranes were  prepared by a  hy- 
potonic lysis method from MDCK cells grown to confluence (3-6 d) in 150- 
mm culture dishes. Each dish was washed twice with 5 ml of ice-cold  lysis 
buffer (1 mM Tris-HCl, 2 mM MgC12, pH 7.5) and incubated with 10 ml of 
lysis buffer for 10 rnin at 4°C. The lysed cells were removed from the dishes by 
scraping with a Costar cell scraper.  The dishes were washed once with 5 ml of 
lysis buffer, and the pooled lysate was centrifuged at 30,000g for 10 rain at 4°C. 
The pellet was washed two more times with lysis buffer and resuspended  in ice- 
cold incubation buffer (145  mM NaCI, 20 mM Tris-HCI, 2 mM MgCI2, pH 
7.5).  This procedure  resulted in  uniform lysis of the  cells.  The  resulting 
preparation consisted of cell membrane "ghosts" and all of the nuclei could be 
stained by the addition oftrypan blue. The cell concentration in the suspension 
was determined for each experiment by mixing 100 #1 of suspension and 100 
#i of 0.4% trypan blue and then counting the intact, trypan blue-stained nuclei 
in a  hemacytometer. Membrane protein was determined by the method of 
Lowry (25)  using bovine serum albumin standards. The protein content was 
0.146 +  0.03 my/10  ~ lysed cells and was ~  15% higher for subconfluent cells 
than for confluent cells. 
Radioligand Binding Assays:  Binding assays were  performed.in 
duplicate or triplicate by incubating  0.125-0.2 ml of freshly  prepared membrane 
suspension  (0.5-3 ×  10  ~ cells/tube)with 0.025 ml of [J25I]ICYP or [mI]IHEAT 
or 0.05 ml of [3H]prazusin and 0.025-0.1 ml of various drugs in a final volume 
of  0.25 ml (0.5 ml for [3H]prazusin) in polypropylene test tubes (16 ×  105 ram, 
Walter Sarstedt,  Inc., Princeton, NJ). Assays were initiated by the addition of 
membrane and were carried out in incubation buffer (145 mM NaC1, 20 mM 
Tris-HCl, 2 mM MgCI2, pH 7.5). For equilibrium binding studies, membranes 
were incubated for 60 rain at 37°C in a shaking water bath (~80 cycles/rain). 
The incubation was terminated by the addition of 10 ml of 37°C incubation 
buffer.  Bound and  free  radioligand were  then separated by rapid  (<10  s) 
filtration over Whatman GF/C glass fiber filters (Whatman Ltd.) on a Millipore 
filtration manifold (Millipore  Corp., Bedford, MA), and the filters were washed with 10 ml of 37°C incubation buffer. Radioactivity retained on the filters was 
determined using a Searle gamma counter (Searle Analytic, Inc., Des Plaines, 
IL) at 63% efficiency (~2sI), or with 4.5 ml of scintillation cocktail in a Beckman 
scintillation counter (Beckman Instruments, Inc., Fuilerton, CA) at 30% effi- 
ciency (3H). Nonspecific binding was defined with the following agents: for [3HI 
prazosin and [3H]yohimbine, 10 pM phentolamine; for [~251]IHEAT, 0.5 or 1.0 
/~M prazosin; and for [125I]ICYP, 1.0/~M (__.)propranolol. Specific binding was 
determined by  subtraction of nonspecific binding from total  binding. The 
specific  binding was routinely the following  percents of the total binding at 
concentrations of the radioligands near their dissociation constants: >60% for 
[3H]prazosin, >70% for [125I]IHEAT and >75% for [12~I]ICYP. Specific binding 
of the radioligands was linear with cell number. When catecholamines were 
used in binding experiments, ascorbic acid was included at a final concentration 
of 0.5 mg/ml to prevent drug oxidation. Replicate data points varied by <10%. 
Data Analysis:  The dissociation constant (KD) and maximum number 
of binding sites (B~) were determined from Scatchard analysis (40) of satu- 
ration binding isotherms. The line of the Seatehard plot was fitted by linear 
regression analysis. 
Competitive binding curves were analyzed by a  computer program (LI- 
GAND) that performs iterative nonlinear regression (33). 
Phosphatidylinositol Assay:  MDC[(-D cells were seeded in 35-mm 
culture dishes containing 3  rnl of medium find grown to confluence (2 d). 
Assays were performed with triplicate dishes in a humidified 37°C incubator 
with a  5% CO2 atmosphere. Experiments were initiated by rinsing each dish 
twice with 20 ml of 37°C Krebs-Henscleit buffer (KHB:  118 mM NaCi, 4.7 
mM KCI, 3.0 mM CaCI2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 0.5 mM EDTA, 
25 mM NaHCO3, and 10 mM glucose, pH 7.4) and then adding 750/~1 ofmyo- 
[3H]inositol (6.6 Ci/mmol, ~4.5/~Ci/dish) in KHB. 60 min later, 7.5 pl of drug 
or control  solution was added,  and the incubation was continued for  an 
additional 30 rain. Ascorbic acid (5 mg/ml) was included in the freshly  prepared 
epinephrine stock solutions to prevent drug oxidation bafore addition to the 
cells (final concentration, 0.05 mg/ml). Incubations  were terminated by removal 
of the incubation mixture by aspiration followed by three washes with 2 ml of 
ice-cold saline. Cold saline (0.5 ml) was then added, and the cells were removed 
from each dish by scraping. Each dish was washed two more times with 0.5 ml 
of cold saline, and the pooled washes were centrifuged for 30 s in a microfuge. 
The supernatant was removed, and 0.75 mi of ice-cold  chloroform/methanol 
(1:2) was added to the pellet. The termination procedure was completed in <3 
rain. 
Phosphatidylinositol (PtdIns) was extracted by the addition of 0.2 ml of 2 
M  KCI to each sample (final proportions of chloroform/methanol/2 M  KCI, 
10:5:4) followed by sonication using a Kontes cell disrupter in three 10-s bursts. 
A two-phase system was formed by the addition of 0.25 ml of chloroform and 
0.25 ml of 2 M  KCI followed  by centrifugation at 1,600g for 20 min at 4°C. 
The aqueous upper phase and any interfacial material were  removed, the 
organic lower phase was decanted, and the remaining  tissue pellet was discarded. 
The lower phase was washed twice with 0.5 ml of chloroform/methanol/water 
(3:47:48) and dried under N2, and the tritium content was determined in 3.5 
ml of OCS  scintillation cocktail  (Amersham)frriton X-100 (2:1).  Control 
experiments showed that <0.05% of the free myo-[3H]inositoi  contaminated 
the lower phase and that  100  +  1% of the total  lower phase counts were 
recovered as PtdIns, as determined by lipid separation by two-dimensional 
thin-layer chromatography (first dimension: chloroform/methanol/water/18 M 
NI-I4OH, 130:70:8:0.5; second dimension: chloroform/acetone/methanol/acetic 
acid/water,  10:4:2:2:1) on 20  x  20-cm silica  gel glass plates (Merck & Co., 
Rahway, NJ) (36). 
cAMP Assay:  MDCK cells were grown to confluence (1-3 d; ~ 5 x  105 
cells/well) in 24-v~11 culture dishes. The medium was removed by aspiration, 
and the cells were washed twice with  1 ml of Hanks' balanced salt solution. 
Incubation medium (0.4 ml) consisting of a freshly prepared solution of drugs 
in HBSS was then added, and the dishes were incubated at 37°C for 5 rain. At 
the conclusion of the incubation, 100 pl of 40% trichloroacetic acid was added 
to each well. After a 10-rain incubation at room temperature, the trichloroacetic 
acid extracts were removed from each well and transferred to 0.5 ml Dowex 
AG 1 x  8 columns. The columns were washed with 2.5 ml of water, and the 
cAMP was eluted with 4  ml water. Recovery of the cAMP was 90-95% as 
determined in control columns using [3H]cAMP. The cAMP ¢luate was dried 
with a Speedvac concentrator (Savant Instruments,  Inc., Hicksville, NY). Cyclic 
AMP was measured by a competitive binding protein assay using aliquots of 
the dried sample fractions resuspended in sodium acetate buffer (18,  19). 
RESULTS 
MDCK Cell Lines 
The results of our initial radioligand binding experiments 
with  MDCK  membranes indicated that  MDCK cells  pos- 
sessed both at- and/~2-adrenergic receptors. These receptors 
are described in subsequent sections. We found, however, that 
the  expression of at-receptors varied  in  MDCK cell lines 
obtained from different sources. Our in'st experiments were 
conducted  using  MDCK  cells  derived  from  ATCC  stock 
culture that had been maintained in the laboratory of Dr. 
Saier.  These cells  had approximately equal numbers of al- 
and B2-receptors (Table I). When we obtained cells directly 
from ATCC, we found that early passage cultures had more 
TABLE  I 
Summary of the Morphologic and Adrenergic Receptor Properties of MDCK Parental and Clonal Cell Lines 
Adrenergic Receptors 
Cell Line  Origin  Morphology  Domes  Alpha1  Beta2 
sites~cell 
Parental: 
ATCC  ATCC,  p53  M  and NM  +  1,200  1,100 (p56) 
1,100  2,300 (p60) 
0  3,100 (p75) 
ATCC  M. Saier  M, F  +  4,600  3,900 
Clonah 
C  ATCC,  p59  NM, F  +  0  1,800 (p7) 
D  ATCC, p59  M, F  +  7,900  470 (p7) 
H  ATCC, p68  NM, C  -  0  970 (p7) 
L  ATCC, p68  NM, C  +  0  6,300 (p7) 
M  ATCC, p68  NM, F  -  0  740 (p8) 
N  ATCC, p68  NM, F  -  0  960 (p7) 
Q  SF  M, F  +  15,000  1,600 (p5) 
R  SF  M, F  +  13,000  2,500 (p6) 
S  SF  M, F  +  15,000  3,100 (p5) 
T  SF  M, F  +  22,000  3,200 (p4) 
U  SF  M, F  +  19,000  1,100 (p5) 
The origin column indicates the cell line from which each cell line was derived. The morphology column refers to the appearance of the cells when seeded at 
low density.  "Domes" refers to the presence or absence of multicellular domes (or hemicysts) in confluent monolayers as observed over ~20 passages  of 
continuous growth. The number of sites for both adrenergic  receptor subtypes was determined in parallel at the indicated passage number by Scatchard 
analysis of radioligand-binding isotherms as described  in the text. ATCC, American Type Culture Collection; SF, ATCC stock from Saier%  laboratory grown in 
serum-free medium for 6 mo and then returned to serum-containing  medium; NM, nonmotile; M, motile; F, flattened; C, cuboid; p, passage  number, for clonal 
cell lines this refers to the number of passages  after cloning. 
MEIER ET AL.  el- and ~g-Adrenergic  Receptors  in MDCK  Cells  407 /~2-receptors than arreceptors (Table I) and that the number 
of a,-receptors  decreased  with  increasing  passage  number. 
The two cell lines were maintained in our laboratory under 
identical culture conditions. To resolve the problem of vari- 
able a,-receptor expression, we cloned early-passage ATCC 
cells (MDCK-ATCC) by limiting dilution and obtained sev- 
eral clonal cell lines. In addition, we cloned cells that we had 
originally obtained from Dr. Saier's laboratory but that had 
been  grown  in  serum-free  medium  for  ~6  mo  and  then 
returned to serum-containing medium (MDCK-SF). 
Phase-contrast micrographs of several representative clonal 
lines are shown in Fig.  I. When ATCC cells were seeded at 
low density, cells with different morphologies were observed 
within the population (Fig.  1A). Some colonies consisted of 
cells that were elongated and flattened, while others contained 
more cuboid cell types. Clones derived from parent popula- 
tions were homogeneous but exhibited distinct morphologic 
features resembling different elements of the parent popula- 
tion. The morphologic differences between clones were most 
pronounced in subeonfluent cultures and were not as obvious 
in  cells  seeded  at  near-confluent  densities  or  in  confluent 
cultures. Clone R  and other clones derived from MDCK-SF 
had a typical epithelioid appearance (Fig.  l, B and C). At low 
density,  these  clones were extended,  flattened,  and  motile. 
Upon reaching confluency, the cultures formed multicellular 
"domes," which  is  indicative  of apical to  basolateral fluid 
transport (22) (Fig.  1  C). These clones were extremely resistant 
to detachment from their culture substrate by trypsin-EDTA 
at confluency.  A  clone with this same general morphology 
was also obtained from early passage MDCK-ATCC (clone 
D; Fig.  1  D). However, clone D seldom formed domes under 
routine culture conditions. Other clonal lines obtained from 
MDCK-ATCC had strikingly different morphologies. These 
cells were nonmotile, as evidenced by their growth in discrete, 
compact colonies at low cell densities. Some, such as clone L 
(Fig.  1F),  were cuboid  and  did  not  spread on  the  culture 
substrate.  Others,  such  as  clone  M  (Fig.  1  E),  were  more 
flattened but were similarly nonmotile. The majority of the 
nonmotile clones did not form structures that could be iden- 
tiffed as domes by phase-contrast light microscopy. In addi- 
tion, these clones were relatively easily detached from their 
substrate with trypsin-EDTA, even after attaining confluency. 
When cultures were initiated from clonal lines that had been 
stored at -70"C for several months, the morphologies of the 
thawed  cells  were  identical  to  those  of the  original  clone, 
indicating that the  clonal morphologies were stable pheno- 
typic features. 
Clonal MDCK cell lines were screened for their expression 
of a,-  and  #2-adrenergic  receptors  by  radioligand  binding 
techniques  (described  in  the  following sections).  Scatchard 
analyses of radioligand binding isotherms were performed at 
least once with each clone for both a,- and B2-receptors.  As 
summarized in Table I, we found that the nonmotile clones 
did not express at-receptors, as shown by their lack of detect- 
able specific binding of the iodinated al-receptor probe, [t25I] 
IHEAT. The lower limit of detection was ~  100 at-receptors 
per cell. The motile cell lines consistently expressed arrecep- 
tors,  and  all  cell  lines  expressed  B2-receptors.  There  were 
8,000-20,000  at- and 500-6,000/52-receptors per cell in re- 
ceptor-beating cells. Growth of Saier's ATCC cells in serum- 
free defined medium for 2 mo had no acute effect on receptor 
expression, since a,- and/32-receptor numbers on serum-free 
cells (4,600 a,- and 4,000 ~2-receptors/cell) were comparable 
to those of cells grown in serum-containing medium (5,000 
at-  and  3,900  /32-receptors/cell)  when  assayed  in  parallel. 
Therefore,  we attribute  the  high  frequency of al-receptor- 
FIGURE  1  Phase-contrast  photomicrographs of MDCK  parental and  clonal lines.  MDCK  cells were seeded at low density in 
plastic culture dishes and then photographed 1-3 d later with a Nikon inverted microscope equipped with phase-contrast  optics, 
courtesy of Dr. Silvio Varon, University of California, San Diego. (A) MDCK-ATCC,  passage 76. (B) Clone R, subconfluent, passage 
6. (C) Clone R, confluent with dome formation, passage 6. (D) Clone D, passage 22. (E) Clone M, passage 7. (F) Clone L, passage 
7. The passage  numbers refer to the number of passages after cloning, except for the ATCC cells  in which the ATCC  passage 
number applies, x  1,400. 
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the parent cell population. However, after long-term (5 mo) 
growth  in  serum-free  medium,  the  MDCK-SF  cells  had 
13,000 arreceptors and 2,400/~2-receptors per cell. Therefore, 
we cannot rule out the possibility that the increased frequency 
of arreceptor-bearing cells resulted, in part,  from selective 
pressure caused by long-term growth in serum-free medium. 
To study both a~- and/32-adrenergic receptors in a homo- 
geneous cell population, we used clone D.  This clone was 
chosen because it was derived from the early-passage  ATCC 
stock and was therefore most likely to reflect properties of the 
renal cell from which it was derived. The morphology and 
adrenergic receptor expression of clone D  have been stable 
for over 50 passages  since initial cloning.  In the  following 
sections we  will  describe adrenergic receptor properties in 
both parental (MDCK-ATCC) and clonal (MDCK-D) lines. 
a~-Adrenergic Receptor Characterization 
Two  subtype-selective a-adrenergic antagonists,  [3H]pra- 
zosin and  [3H]yohimbine, which  we  have found useful  in 
identifying renal a~- and c~2-receptors, respectively (42), were 
used in initial binding experiments with parental MDCK cells. 
No specific binding of [3H]yohimbine was detected in several 
experiments, indicating that MDCK cells did not express ot2- 
adrenergic receptors.  In  contrast,  specific binding  of [3H] 
prazosin was consistently observed, suggesting that al-recep- 
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FIGURE  2  Kinetic analyses of [3H]prazosin and [USl]IHEAT binding 
to MDCK  membranes.  Specific  binding of 0.50  nm  [3H]prazosin 
(upper panel) to MDCK  and 0.13  nM  [7251]IHEAT (lower panel) to 
MDCK-D  membranes at 37°C was followed as a function  of time 
(filled circles). After 60 min, the rate of dissociation of the radioli- 
gands (circles) was followed subsequent to the addition of phen- 
tolamine to a final concentration of 10 pM (for [3H]prazosin, upper 
panel) or prazosin to a final concentration of 1 pM (for [~251]IHEAT, 
lower  panel).  Each  data  point  represents  the  mean  of  duplicate 
samples. The data are expressed as  percent of maximum specific 
binding as defined in the text. 
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FIGURE 3  Saturation binding isotherms for [3H]prazosin and [1251] 
IHEAT on MDCK membranes. MDCK membranes were incubated 
with the indicated concentrations of [3H]prazosin (upper  panel) or 
[1251]IHEAT (lower panel) for 60 min at 37°C. Conditions for the 
binding assay and the determination of specific  binding are de- 
scribed  in the text. The insets show the Scatchard analyses of the 
binding data used to determine the equilibrium dissociation  con- 
stants (Ko), binding site numbers (Bmax),  and Hill coefficients.  These 
data were obtained in a single experiment using the same mem- 
brane preparation for both radioligands. Each data point represents 
the mean of triplicate determinations. 
tors were present on MDCK. 
Further characterization of the specific [3H]prazosin bind- 
ing sites showed that these sites demonstrated properties ex- 
pected for ~-adrenergic receptors. A kinetic analysis of [3H] 
prazosin binding to MDCK membranes is shown in Fig.  2 
(upper  panel). Specific binding reached equilibrium rapidly at 
37"C, with saturation occurring in 20 rain. Upon addition of 
10 pM  phentolamine (the a-adrenergic antagonist  used  to 
define nonspecific binding), specific [3H]prazosin binding dis- 
sociated with a half-time of 18 min and was totally reversible. 
The specific binding of [3H]prazosin was saturable, as shown 
in Fig. 3 (upper  panel). In this representative experiment, the 
maximum number of binding sites (Bmax) was 5,700 sites per 
cell. Scatchard analysis of the equilibrium binding isotherm 
indicated the presence of a single class of binding sites with a 
KD of 0.74 _+ 0.3 nM (n =  4). The noncooperative nature of 
the binding sites was indicated by a Hill coefficient of unity 
(1.08  +  0.09). When  [3H]prazosin binding assays were per- 
formed in the presence of competing adrenergic ligands,  the 
results were consistent with binding to a pure population of 
a~-receptors (Fig. 4). Indoramin, a classic al-antagonist, had 
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FIGURE 4  Competition for  [3H]prazosin  and  [~251]IHEAT binding 
sites by adrenergic agonists and antagonists. The binding of 0.6 nM 
[3H]prazosin (upper  panel) or 0.4 nM [~251]IHEAT (lower  panel) to 
MDCK membranes was measured in the presence of the indicated 
concentrations of competing ligands. Data are expressed as percent 
of maximum specific  binding as defined in the text. The curves 
were fitted to one-site models by the LIGAND program. Each data 
point represents the mean of triplicate determinations, and each 
panel shows data  obtained for different ligands  using the same 
membrane preparation. 
an affinity for the [3H]prazosin binding sites 19 times higher 
than did the aE-antagonist yohimbine. Using the LIGAND 
curve-fitting program,  we  were  able  to  determine  whether 
competing drugs bound to a single site with one affinity ("one- 
site fit") or whether the binding was better described by two 
(or more) sites with different affinities ("two-site fit") (33). 
The subtype-selective antagonists bound to a single popula- 
tion of receptors, inasmuch as fits of the competition binding 
data  for these  drugs  based  on  a  two-site  model  were  not 
significantly  improved  over fits  to  a  one-site  model.  [3H] 
Prazosin bound  to stereoselective sites,  as evidenced by the 
severalfold higher  affinity of (-)-epinephrine  as  compared 
with (+)-epinephrine; this result is as expected for a-adrener- 
gic receptors (42). 
a-Adrenergic  binding  sites  were  also  identified  with  the 
iodinated  arselective antagonist,  [~25I]IHEAT (9,  13). The 
higher specific activity of  this ligand compared to [3H]prazosin 
allowed  binding  experiments  to  be  performed  with  fewer 
MDCK cells. [~25I]IHEAT bound to a~-receptors that had the 
same properties as the receptors identified with [3H]prazosin. 
Binding of [~25I]IHEAT at 37"C was saturable, achieved equi- 
librium in 50 min, and was totally reversible upon the addi- 
tion of excess unlabeled prazosin (0.5 pM, the concentration 
used to define specific binding) with a half-time of  dissociation 
of 8  rain  (Fig.  2,  lower panel).  Scatchard  analysis of [~25I] 
IHEAT binding is shown in Fig.  3 (lower panel). This assay 
was conducted in parallel with the [3H]prazosin binding assay 
shown  in  Fig.  3  (upper  panel)  with  the  same  membrane 
preparation.  [~25I]IHEAT  bound  with  high  affinity  (Ko  = 
0.151  +  0.07 nM [n =  8]) to a single class of noncooperative 
binding sites (Hill coefficient =  1.03 +  0.04).  Comparison of 
the  upper  and  lower  panels  of Fig.  3  shows  that  similar 
numbers of sites were identified with  [~25I]IHEAT and [3H] 
prazosin (5,000 vs. 5,700 sites/cell).  The results of  competitive 
binding assays are shown in Fig.  4 and are summarized in 
Table II. The finding that the affinity of unlabeled HEAT was 
18 times lower than that of [J25I]IHEAT confirms a  similar 
observation by Glossman et al. (13). Prazosin was more potent 
than yohimbine, and (-)-epinephrine was more potent than 
(+)-epinephrine. These data indicate that both [3H]prazosin 
and [z25I]IHEAT are suitable ligands for the identification of 
a~-adrenergic receptors of MDCK cells. 
t32-Adrenergic Receptor Characterization 
~-Adrenergic receptors were identified  on  MDCK mem- 
branes with [~25I]ICYP, a high-affinity B-antagonist that binds 
with equal affinity to both/3~- and 132-receptor subtypes (10). 
The  kinetics  of association  and  dissociation  of [tz5I]ICYP 
from  MDCK  membranes  is  shown  in  Fig.  5.  [J25I]ICYP 
specific binding reached equilibrium in 40 min at 37"C and 
was slowly dissociable (tv2 ~  300 min) upon the addition of 
1 pM propranolol. [~25I]ICYP specific binding was saturable, 
with maximum binding to 2,100 sites/cell in this representa- 
tive experiment. Scatchard analysis of  the equilibrium binding 
isotherm  (Fig.  6)  showed  a  single  class  of noncooperative 
binding sites with a Ko of 0.051  +  0.03 nM (n =  12) and a 
Hill coefficient of  1.00  _+  0.09.  The results of competitive 
binding assays are shown in Fig.  7  and are summarized in 
Table II. The [~25I]ICYP binding sites were determined to be 
~2-receptors  on  the  basis  of the  dissociation  constants  of 
catecholamine agonists (isoproterenol <  epinephrine << nor- 
epinephrine. The subtype-selective antagonists practolol (/30 
and IPS 339 032) each bound to a single class of binding sites, 
since  their  competition  binding  data  were  adequately  de- 
scribed by one-site models. From these results,  we conclude 
that MDCK cells have a pure population of #2-receptors and 
have  no  detectable  Bt-receptors.  (-)-Propranolol  was  210 
times more potent than (+)-propranolol, and (-)-isoproter- 
enol was 23 times more potent than (+)-isoproterenol, indi- 
cating that the [125i]ICYP.binding  sites had the stereoselectiv- 
ity expected of B-adrenergic receptors. 
Stability of Receptor Expression in Clone  D 
The presence of both al- and ~2-receptors on a number of 
clonal MDCK lines showed that these two receptor types were 
expressed on the same cell. The pharmacologic properties of 
the al- and B2-receptors  of clone D  were similar to those of 
the parent cell lines (Table II). A subclone of clone D  (D-l) 
also coexpressed a~- and/32-receptors, confirming that these 
receptors were present on a single  cell.  To use clone D  as a 
model system in  which to examine these receptors, we re- 
quired evidence that the receptor expression was stable with 
time in culture. Scatchard analyses of radioligand binding to 
a~- and ~2-receptors in early- and late-passage MDCK-D cells 
are shown in Fig.  8.  Receptor numbers were compared be- 
tween cells that had been maintained for 53  passages since 
initial cloning from the parent line and cells that had been 
grown from frozen early-passage stock and had been main- 
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Summary of Equilibrium Dissociation Constants for Adrenergic Ligands in MDCK 
KD 
Radioligand  Competing Ligand  ATCC  Clone D 
nM 
I.  Alpha 
A.  [3H]prazosin  --  0.074 ±  0.03 
Antagonist:  Indoramin  20  1 
phentolamine  140  -- 
yohimbine  380  -- 
Agonist:  clonidine  1,400  -- 
(-)-epinephrine  6,200  -- 
(-)-norepinephrine  18,000  -- 
(+)-epinephrine  120,000 
B.  [TZSl]IHEAT  --  0.151 ±  0.07  0.186 ±  0.03 
Antagonist:  prazosin  0.048  0.076 
H EAT  --  2.8 
indoramin  --  24 
phen0xybenzamine  --  46 
phentolamine  640  -- 
yohimbine  1,100  4,100 
Agonist:  (-)-epinephrine  2,100  2,200 
(+)-epinephrine  --  87,000 
II.  Beta-adrenergic receptors 
A.  [~ZSl]ICYP  --  0.051 ±  0.03  0.031 ±  0.02 
Antagonist:  I PS 339  0.19  -- 
(-)-propranolol  0.36  -- 
(+)-propranolol  77  -- 
practolol  7,200  -- 
Agonist:  (-)-isoproterenol  35  23 
(-)-epinephrine  44  280 
(+)-isoproterenol  800  -- 
(-)-norepinephrine  3,300  3,000 
KDS for the radioligands were determined by Scatchard analysis of equilibrium binding isotherms; KDS for unlabeled agonists and antagonists were determined 
from the concentrations that reduced specific radioligand binding by 50% and in all cases were estimated by the LIGAND program using a one-site model to 
fit the data. Each value was derived from a single experiment in which several other ligands were concomitantly tested, so that their rank orders of potency 
might be easily compared. 
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FIGURE  5  Kinetic  analysis of  ['2Sl]ICYP  binding to MDCK  mem- 
branes. Specific binding of 0.07 nM [12Sl]ICYP to MDCK membranes 
at 37°C was followed as a function of time (filled circles). After 60 
rain,  the  rate of  dissociation  of  [12Sl]ICYP  (circles)  was  followed 
subsequent to the addition of (_)-propranolol to a final concentra- 
tion of  1 ~M.  Each data  point  represents the  mean of duplicate 
determinations. The  data are expressed as  percent  of  maximum 
specific binding as defined in the text. 
mined  for  11  passages since  cloning.  The  early- and  late- 
passage cells,  when grown and assayed under identical con- 
ditions, expressed identical numbers of ~]- and/~2-adrenergic 
receptors, indicating  that  receptor expression in  MDCK-D 
was not altered during prolonged maintenance in culture. 
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FIGURE  6  Saturation  binding  isotherm  of  [12Sl]ICYP  to  MDCK 
membranes. MDCK-D  membranes were incubated with  the indi- 
cated concentrations of ['251]ICYP  for 60 rain at 370C, and specific 
binding was determined as described in the text. The inset shows 
a  Scatchard  analysis of the  equilibrium  binding  data, which  was 
used to calculate the KD, B  .... and Hill coefficient.  Each data point 
represents the mean of triplicate determinations. 
Guanine Nucleotide Modulation of 
Agonist Binding 
Guanine nucleotides are known to lower the affinity of/3- 
adrenergic  agonists  for their  receptors (44)  and  have been 
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FIGURE 7  Competition for ['2Sl]ICYP binding to MDCK fl-adrener- 
gic receptors  by adrenergic agonists and antagonists. The binding 
of 0.3  nM  [~2sI]ICYP to MDCK membranes  was measured  in the 
presence  of the  indicated concentrations of competing agonists 
(upper panel) and antagonists (lower  panel). The data were fitted to 
one-site models by the  LIGAND  program  and are expressed as 
percent of maximum specific  binding as defined in the text. Each 
data  point represents the mean of triplicate determinations, and 
each panel shows data obtained for different ligands using the same 
membrane preparation. 
shown to have a similar but less pronounced effect at renal 
a,-adrenergic receptors (42). We investigated guanine nucleo- 
tide effects on agonist binding to MDCK-D membranes to 
see whether the receptors were differentially sensitive to the 
nucleotide. 
The  effects  of the  nonhydrolyzable  guanine  nucleotide 
guanylyl-5'-imidodiphosphate (Gpp(NH)p) on agonist-bind- 
ing to MDCK-D aj- and fl2-receptors  are shown in Fig. 9. In 
the  lower panel  of Fig.  9,  the  effect of Gpp(NH)p on  the 
affinity of isoproterenol for MDCK-D fl2-receptors  is shown. 
The control curve shown is the two-site fit, which was statis- 
tically superior to the one-site fit (P =  0.003) for these data. 
In this representative experiment, the high-affinity site repre- 
sented 76% of the total sites,  with a KD for isoproterenol of 
15.5 riM. The low-affinity site (24% of total sites) had a KD of 
490 nM. In the presence orguanine nucleotide, the data were 
described adequately by a one-site fit (P >  0.1 for two-site vs. 
one-site fit),  with a  KD for isoproterenol of 470  nM.  These 
data are similar to observations in other fl-receptor systems 
(44).  The effect of guanine nucleotides is thought to reflect 
heterogeneity of agonist binding sites,  in which some of the 
agonist-receptor complexes interact with a GTP-binding reg- 
ulatory protein that mediates the coupling between receptor 
and adenylate cyclase (44).  In the absence of added guanine 
nucleotide, this portion of the agonist-bound receptor popu- 
lation is in a high-affinity state that converts to a low-affinity 
state upon the addition of guanine nucleotide. 
As shown in the upper panel of Fig. 9, Gpp(NH)p did not 
alter the affinity of(-)-epinephrine for MDCK-D a~-receptors 
(KD =  11,000 nM for control and 8,700 nM with Gpp(NH)p). 
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This experiment was repeated several times with both MDCK- 
D  and MDCK ATCC cells and with both [3H]prazosin and 
[~25I]IHEAT, yet no consistent effect of Gpp(NH)p was ob- 
served. The data shown are fit to a one-site model, because 
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FIGURE 8  Comparison of ~,-  and  fl2-adrenergic  binding sites in 
low- and high-passage MDCK-D cells. Membranes prepared from 
clone D cells that had been frozen at passage  6 and then grown to 
passage 11  (left  panels) were analyzed for adrenergic  radioligand 
binding in the same experiment with  membranes  prepared from 
clone D cells grown for 52 continuous passages  since cloning (right 
panels). The Scatchard analyses of the [~2Sl]IHEAT  and  [~2Sl]ICYP 
binding isotherms are shown.  The data are expressed as sites per 
milligram of protein to correct for any differences  in cell size (both 
cultures  were  ~90% confluent). Each data  point represents the 
mean of triplicate determinations. 
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FIGURE 9  Effects  of guanine nucleotide on agonist binding to al- 
and fl2-adrenergic receptors  in MDCK-D. The competition of (-)- 
epinephrine for 0.24 nM [12Sl]IHEAT  sites (upper panel) and of (-)- 
isoproterenol  for 0.13 nM [~251]ICYP  sites (lower panel) was assessed 
in  the  presence  (circles)  and  absence  (filled circles)  of  100 #M 
Gpp(NH}p using membranes prepared from MDCK clone D. The 
data  shown are  LIGAND-determined one-site fits  for  all curves 
except for the isoproterenol control, in which the data were better 
described by the two-site fit.  Each data point represents the mean 
of triplicate determinations. fits to a two-site model were not significantly better (P >  0.1 
for two-site vs. one-site fit).  These results show that MDCK 
a~-  and  ~2-receptors are  not  affected in  the  same way by 
guanine nucleotides. 
Phosphatidylinositol Turnover 
The  effect of epinephrine  on  the  incorporation  of [3H] 
inositol into phosphatidylinositol (Ptdlns) was examined to 
determine whether a j-receptors in MDCK cells are function- 
ally coupled to this putative second-messenger system, as has 
been observed for at-receptors in other tissues (11).  MDCK- 
D  cells were  prelabeled with  myo-[3H]inositol for 60  min, 
exposed to various concentrations of (-)-epinephrine for an 
additional  30  min,  and  the incorporation  of the  label into 
cellular Ptdlns was determined (Fig.  10). In the presence of 
epinephrine the rate of incorporation of [3H]inositol increased 
to a maximum of 92% above the baseline levels seen in the 
absence  of epinephrine  (Fig.  10). A  half-maximum  effect 
(ECso) occurred with  1.8  t~M  epinephrine,  a  concentration 
similar to the Ko of epinephrine in the binding studies (Table 
2).  The response to epinephrine was totally blocked by the 
simultaneous addition  of 1 uM  prazosin (Fig.  10), whereas 
prazosin alone had no effect on inositol incorporation (data 
not shown). Epinephrine stimulation of myo-[aH]inositol in- 
corporation into  Ptdlns  was also observed when  cells were 
prelabeled with myo-[3H]inositol for 30 min, rather than 60 
min,  before drug  addition  (data  not  shown).  These results 
indicate that a,-receptor occupation stimulates Ptdlns synthe- 
sis in MDCK cells. 
Cyclic AMP Accumulation 
The effect of isoproterenol on cyclic AMP accumulation in 
MDCK cells was studied to determine whether the/~2-recep- 
tors were coupled to adenylate cyclase. When ATCC-derived 
cells were incubated with isoproterenol,  a  rapid increase in 
cAMP accumulation  was observed.  In the  presence of 0.5 
mM isobutylmethylxanthine, a  phosphodiesterase inhibitor, 
the cAMP attained a maximum level after 5 min of isopro- 
terenol exposure (data not shown).  The dose-response rela- 
tionship for this effect (Fig.  11, left) indicated that the ECso 
for  isoproterenol  was  0.1  #M.  Epinephrine  also  increased 
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FIGURE 10  Stimulation of phosphatidylinositol  turnover in MDCK- 
D by epinephrine. MDCK clone D cells were incubated with myo- 
[3H]inositol for 60 rain at 37°C.  The indicated concentrations of 
epinephrine were then added, and the incubation was continued 
for 30 min. The assay was terminated, and Ptdlns was extracted as 
described in the text. The data are expressed as the percent increase 
in myo-[3H]inositol incorporation into Ptdlns compared with con- 
trol. The data obtained when 1 #M prazosin was added concomi- 
tantly with 10  -4 M  epinephrine are indicated on the figure by the 
circle. Each data point represents  the mean of triplicate determi- 
nations. 
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FIGURE 11  Stimulation of cAMP accumulation in MDCK by isopro- 
terenol  and  epinephrine. MDCK  cells  were  incubated with the 
indicated concentrations of (-)-isoproterenol (/eft panel). The right 
panel  represents  cells  incubated  in  the absence of epinephrine 
("basal"),  with epinephrine in  the presence and absence of pro- 
pranolol, or with propranolol alone. The data points shown repre- 
sent means of triplicate determinations +  SEM and are expressed 
as picomoles of cAMP per well (of a multiwell culture plate) per 5 
min. Data in both panels were obtained using the same cell prep- 
aration. 
cAMP  accumulation,  and  this  increase  was  completely 
blocked by  1 #M  propranolol (Fig.  11,  right).  Propranolol 
alone had no effect on cAMP levels.  Isoproterenol increased 
cAMP levels to a  similar extent in  several clonal cell lines. 
The increase in cAMP content over baseline levels in response 
to  l0  -5 M  isoproterenol was 978,  1,030,  and  1,077  pmoles 
cAMP/107 cells/10 min for clones D, L, and N, respectively. 
These results show that enhanced cAMP accumulation was 
promoted by agonist occupancy of fl-adrenergic receptors in 
MDCK cells. 
DISCUSSION 
In this study we have shown that MDCK renal epithelial cells 
have ~z- and #2-adrenergic receptor subtypes, that both recep- 
tor types can be expressed by a single cell, that the receptors 
show different sensitivity to guanine nucleotides, and that ~l- 
and fl2-receptors  mediate distinct intracellular responses. The 
radioligand binding experiments showed that a- and B-recep- 
tors of MDCK can be classified as classic al- and fl2-receptors 
and that there are no detectable a2- or/31-receptors. In con- 
trast, studies of membranes prepared from kidney cortex have 
indicated that the number of a2- and fit-receptors is two to 
three times greater than that of at- and #2-receptors (41-43), 
suggesting that MDCK cells represent only a minor portion 
of the adrenergic receptor-bearing cells in the kidney cortex. 
Our findings suggest that growth of MDCK in vitro does not 
alter the recognition properties of these receptors, inasmuch 
as the  receptors show  binding  specificities characteristic of 
classic a~- and fl2-adrenergic  receptor subtypes. In this regard, 
it is interesting that the affinity of the endogenous agonists 
norepinephrine  and  epinephrine  for  fl2-receptors  is  much 
higher than that for c~j-receptors of MDCK cells. 
The  findings further our understanding  of the  nature  of 
adrenergic receptors in renal tubules. The functions of renal 
a~-receptors are poorly understood, and these receptors have 
been thought to be located primarily on the renal vasculature 
(20, 41).  However, recent studies indicate that renal a~-recep- 
tors mediate gluconeogenesis (27),  which probably occurs in 
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receptors may regulate  ion  and  water reabsorption  by the 
nephron (6, 20, 32,  35). The results of our experiments with 
MDCK  cells provide direct  evidence that  at-receptors are 
located on  renal tubule  epithelium.  Further,  although data 
indicating that B-adrenergic receptors are present on tubule 
epithelium  have been  presented  (7,  20,  31),  we show that 
tubule cells can possess a "pure" population of BE-adrenergic 
receptors. Our findings imply that the administration of  drugs 
acting at al- and B2-adrenergic  receptors may perturb tubule 
cell function. Because at- and 132-receptor subtypes are present 
on several clonal isolates from parent MDCK cells,  at least 
some (but probably not all) tubule cells are able to express 
both receptor subtypes. Additional work will be required to 
determine exactly which tubular cells in vivo possess one or 
both types of adrenergic receptors. 
Previous work has indicated that a- and 13-adrenergic recep- 
tors are regulated quite differently by guanine nucleotides and 
other factors in target cells.  However, few studies have been 
performed with cells of which  one could be confident that 
both classes of receptors are  simultaneously expressed (18, 
34). As observed in other systems (44), Gpp(NH)p shifted the 
high-affinity component of agonist binding to /3-adrenergic 
receptors of MDCK cell membranes to a lower affinity, such 
that  only low-affinity sites were detected.  In contrast,  epi- 
nephrine bound to a single class of al-receptor sites on MDCK 
membranes, and the affinity of these sites for agonist was not 
altered by guanine nucleotide, at-Receptors are not generally 
thought to be coupled to adenylate cyclase or to a guanine 
nucleotide regulatory protein. However, in other aj-receptor 
systems guanine  nucleotides  have been  shown  to decrease 
agonist affinity (l 4, 22).  a l-Receptors of MDCK cells appear 
to be in a homogeneous (pseudo-Hill slope for epinephrine = 
0.87  +  0.05  In  =  3]),  low-affinity state  in  the  absence  of 
guanine  nucleotide,  and  this  may account  for the  lack  of 
guanine nucleotide effect. This lack of regulation of ~-recep- 
tors  by guanine  nucleotides  may  reflect  properties  of the 
native receptors or may be secondary to the membrane prep- 
aration or incubation conditions. 
In addition to differences in receptor regulation by guanine 
nucleotides,  our findings show important differences in the 
linkage of at- and ~32-receptors to second-messenger systems. 
Activation of adenylate cyclase by catecholamines in  renal 
membranes and  in  MDCK  cells  has  been  correlated with 
changes in transepithelial transport (20,  35).  We have con- 
firmed that adenylate cyclase activation is  mediated by B- 
receptors (in MDCK, by/3E-receptors). ~xrAdrenergic stimu- 
lation, in a variety of systems, results in calcium mobilization 
and alterations in membrane phospholipid metabolism ( 1 l). 
The stimulation of PtdIns synthesis by at-agonists in MDCK 
may be a  key step in the events resulting from a:receptor 
occupation,  a-Adrenergic stimulation of PtdIns synthesis is 
thought to result from initial stimulation of PtdIns hydrolysis 
(1 l),  which  may result in  the  release of arachidonic  acid, 
which may in turn result in increased prostaglandin synthesis. 
a-Adrenergic-induced  changes  in  prostaglandin  synthesis 
have been reported for MDCK cells (23).  Our data suggest 
that alterations in PtdIns metabolism may be an initial step 
in this response. 
In  spite  of differences in receptor recognition  properties 
and  in  linkage  to  second-messenger systems,  it  has  been 
suggested that a- and/3-adrenergic receptors may be located 
at separate sites on the same protein or may be interconver- 
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tible entities (21). Most recently, receptor interconversion has 
been suggested as a mechanism to account for temperature- 
induced changes in adrenergic effects on renin release by the 
kidney (5). Thus far, we have found no evidence for receptor 
interconversion  in  clonal  MDCK  cells.  MDCK  cells  can 
express both at- and ~2-receptors or only/32-receptors. The 
receptors behave as distinct macromolecules in terms of their 
modulation by guanine nucleotide, apparently because they 
are coupled to different regulatory proteins.  Each  receptor 
mediates discrete biochemical responses: at-agonists increase 
PtdIns turnover, and/32-agonists increase cAMP levels,  indi- 
cating that the receptors likely are discrete entities. In addi- 
tional studies we have obtained preliminary data on receptors 
solubilized from clone D, indicating structural differences in 
a~- and/32-receptors from these cells (45). 
In this study we also obtained information regarding the 
heterogeneity of the  MDCK cell  line showing that MDCK 
clones differ in morphology and in adrenergic receptor expres- 
sion. Expression of at-receptors was observed only in motile 
clones but was not correlated with  the ability of clones to 
form domes.  Clonal morphologies and  receptor expression 
were stable phenotypic features, which suggests that the var- 
ious cell types were present in the parent cell line and did not 
arise by spontaneous mutation. Morphologic differences be- 
tween clonal MDCK lines have been observed by others (22, 
47).  Differences in ion transport (37)  and arachidonic  acid 
metabolism (24) between different nonclonal MDCK sublines 
have been noted. Variations between nonclonal MDCK sub- 
lines  may have  arisen  by selection  for one  cell  type  over 
another during maintenance in culture. Inasmuch as MDCK 
was derived from a mince of kidney cortex (12),  cell hetero- 
geneity is not unexpected. MDCK cells appear to be derived 
mainly from distal tubule/collecting duct;  however, hetero- 
geneity of cell types exists even within these segments. Val- 
entich (47) has suggested that two MDCK cell types may be 
derived from the principal and intercalated cells of the col- 
lecting duct. Our data confirm his conclusions regarding the 
stability of morphologically distinct  clones,  but  additional 
studies will be required to draw further analogies between our 
clonal  lines  and  the  cell  types  identified  by Valentich.  In 
addition,  we have not  yet determined the  cellular factor(s) 
that result in the expression of the motile phenotype. MDCK 
cells  synthesize basal lamina when grown  on collagen (47) 
and also release biomatrix components when grown on plastic 
(4).  Clonal  variations in  the  production  of such  molecules 
may affect cell attachment and motility, but this hypothesis 
will  require  further study.  We  believe that  cloned  MDCK 
cells will serve as unique model systems for further studies of 
the cellular regulation of renal adrenergic receptors and for 
evaluating other cellular properties of this cultured renal cell 
line. 
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